Postoperative complications in neoadjuvant treatment including bevacizumab for HER2-positive inflammatory breast cancer (IBC): Results from a phase II prospective trial. Background: Previous trials ...

Primary central nervous system lymphoma: The influence of radiotherapy on patient outcome in an unselected population. PC or PCV? That is the question: A retrospective review of primary anaplastic ...

Temozolomide is an alkylating cytostatic drug that finds increasing application in the treatment of melanoma, anaplastic astrocytoma and glioblastoma multiforme. The compound is a prodrug that ...

Oct. 21, 2003 (San Francisco) — The alkylating agent temozolomide (Temadar; Schering-Plough) is showing long-term safety and efficacy in the treatment of malignant gliomas in a study that is ...

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas. The randomized phase 3 ...

September 14, 2009 — Results from a phase 2 trial of lapatinib (Tykerb) in liver cancer were disappointing, with benefit seen only in a small subgroup of patients who developed a rash while ...

Lapatinib reduces the number of large brain metastases in a mouse model of metastatic breast cancer, relative to untreated mice, researchers report. Lapatinib reduces the number of large brain ...

Veliparib addition to temozolomide did not significantly extend overall survival in MGMT-hypermethylated glioblastoma patients. The investigational combination was well tolerated, with no significant ...

Lapatinib is an oral inhibitor of HER2 and thus interferes with the mechanism of tumour growth. This study assessed 126 patients, all with inflammatory breast cancer, who were treated with ...

Boston (March 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...